Navigation Links
Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients
Date:3/13/2008

rome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection fraction has been reported, including reports in patients with few or no risk factors for decreased left ventricular ejection fraction. There have been rare reports of acute diffuse infiltrative pulmonary disease of unknown etiology such as pneumonitis, interstitial pneumonia, lung infiltration and Acute Respiratory Distress Syndrome in patients receiving VELCADE. Some of these events have been fatal. A higher proportion of these events have been reported in Japan. There have been rare reports of Reversible Posterior Leukoencephalopathy Syndrome (RPLS) in patients receiving VELCADE. RPLS is a rare, reversible, neurological disorder which can present with seizure, hypertension, headache, lethargy, confusion, blindness, and other visual and neurological disturbances. VELCADE is associated with thrombocytopenia and neutropenia. There have been reports of gastrointestinal and intracerebral hemorrhage in association with VELCADE. Transfusions may be considered. Complete blood counts (CBC) should be frequently monitored during treatment with VELCADE. Rare cases of acute liver failure have been reported in patients receiving multiple concomitant medications and with serious underlying medical conditions.

Integrated Safety Data: Safety data from Phase II and III studies of single-agent VELCADE 1.3 mg/m2/dose twice weekly for 2 weeks followed by a 10- day rest period in 1163 patients with multiple myeloma (N=1008) and mantle cell lymphoma (N=155) were integrated and tabulated. In these studies, the safety profile of VELCADE was similar in patients with multiple myeloma and mantle cell
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Tea Ingredients Publication Serves Robust Global Demand for Tea-Based Products
2. New Legal Momentum Publication Exposes How Abstinence-Only Programs Harm Women and Girls
3. Fourth Annual James E. Marshall OCD Foundation Beyond Beauty Dinner to Honor E. Scott Beattie, Chairman and CEO, Elizabeth Arden, Inc. and Charles H. Townsend, President and CEO, Conde Nast Publications
4. Bojan M. Kuure Recognized by Strathmores Whos Who Worldwide Publication
5. Nature publication on pain research
6. CryoCor Reports Publication in Circulation for Treatment of Atrial Fibrillation
7. Fry Construction Is Featured in Key Industry Publication
8. GSA confers 2007 Richard Kalish Innovative Publication Award to USCs Mather
9. Telemedicine publication expands coverage
10. Scientific Publications Strategy & Delivery Shifts from Marketing to Medical
11. Johnson & Johnson Tops Annual Pharmaceutical Company Rankings in a New Report From Industry-Leading Publication Scrip
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... (PRWEB) April 01, 2015 The panel ... and telematics service providers to build a program that ... and complicated legal implications further down the line. This ... wake of the news that OBD-II port dongles aren’t ... In January, it was reported that Progressive’s Snapshot ...
(Date:4/1/2015)... 01, 2015 Taking an important step ... League for Nursing Commission for Nursing Education Accreditation (NLN ... the first NLN CNEA Board of Commissioners. Working with ... the 15-member board will provide leadership and direction to ... accreditation decisions for nursing programs that seek accreditation from ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 EAGAN, Minn. ... Minnesota and its family of companies (Blue Cross) today ... out the year with net income of $61.5 million, ... losses. The organization reported a net operating loss of ... a negative operating margin of one-tenth of one percent ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 GrassrootsHealth, ... announcing two continuing medical education (CME) courses about ... help practitioners become more confident in measuring, prescribing, ... After completion of these CME courses, practitioners can ... The CME courses available are “Vitamin D, Sunshine, ...
(Date:4/1/2015)... 01, 2015 Aging2.0 , the ... announces the launch of the Aging2.0 Alliance ... stakeholders and technology companies. The announcement was made today ... and Business Strategies Forum in San Diego, CA. ... Alliance program is now open for additional members. “This ...
Breaking Medicine News(10 mins):Health News:TU-Automotive: Office of The Privacy Commissioner of Canada To Set Out Privacy Considerations Surrounding UBI Products 2Health News:TU-Automotive: Office of The Privacy Commissioner of Canada To Set Out Privacy Considerations Surrounding UBI Products 3Health News:NLN Commission for Nursing Education Accreditation (NLN CNEA) Announces Inaugural Commissioners 2Health News:NLN Commission for Nursing Education Accreditation (NLN CNEA) Announces Inaugural Commissioners 3Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 2Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 3Health News:GrassrootsHealth Launches CME Courses about Vitamin D 2Health News:GrassrootsHealth Launches CME Courses about Vitamin D 3Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 2Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 3Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 4
... Inc. (Nasdaq: SLTM ), a global leader ... has received regulatory clearance to market and sell Thermage(R) ... opportunity to market the premier non-invasive procedure for tightening ... said Stephen J. Fanning, Chairman of the Board, President ...
... Cites Frequent Hand Washing as Key PrecautionNEW YORK, April ... around the world are taking proactive steps to protect ... over-the-counter flu medication can help you avoid this disease, ... recommending a simpler measure: frequent, thorough hand washing. With ...
... NORCROSS, Ga., April 30 Immucor, Inc. (Nasdaq: ... instrument-reagent systems to the blood transfusion industry, today announced ... America and Merrill Lynch 2009 Health Care Conference in ... simultaneous webcast. The Company,s presentation is scheduled for ...
... figures are in US dollars), - ... - Product sales revenue increases 173%,VANCOUVER, ... today that it recorded revenues of $6,655,342 for the ... ended December 31, 2007. Clinic operations revenue increased 100% ...
... channel blocker, angiotensin receptor blocker and diuretic (amlodipine, ... clinical trial, Exforge HCT demonstrated significantly greater reductions ... dual combinations of its components - Up to ... help control their blood pressure and many need ...
... China Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin ... pharmaceutical products in China, today announced that it ... investor communications best-practices in the U.S. capital markets.Ms. ... stated, "Our decision to hire ICR is part ...
Cached Medicine News:Health News:Solta Medical Receives Regulatory Approval to Market Thermage Systems in China 2Health News:Photos: How You Can Help Protect Yourself & Your Family From Swine Flu (H1N1) 2Health News:Photos: How You Can Help Protect Yourself & Your Family From Swine Flu (H1N1) 3Health News:CRH Medical reports year end results 2Health News:CRH Medical reports year end results 3Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 2Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 3Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 4Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 5Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 6Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 7Health News:China Pharma Holdings, Inc. Retains Global Investor Communications Team 2
(Date:4/1/2015)... , April 1, 2015  The U.S. ... AirStrip® Sense4Baby™ wireless maternal/fetal monitoring ... U.S. by pregnant patients to self-administer non-stress tests ... from the FDA for use accompanied by medical ... the European Commission in 2013 for self-administration, including ...
(Date:4/1/2015)...  Egalet Corporation (Nasdaq: EGLT ) ("Egalet"), ... developing, manufacturing and marketing innovative pain treatments, today ... million aggregate principal amount of its convertible senior ... placement to qualified institutional buyers pursuant to Rule ... amended (the "Act"). Egalet also granted the initial ...
(Date:4/1/2015)... 1, 2015   Advocates for Responsible Care , ... health care professionals, patient advocates and human rights specialists, ... will go live at 9:00 a.m. today. ... Reach is a new campaign to limit rising out-of-pocket ... by Advocates for Responsible Care, in partnership with the ...
Breaking Medicine Technology:AirStrip Sense4Baby System Receives FDA Clearance for Patient Self-Administration 2AirStrip Sense4Baby System Receives FDA Clearance for Patient Self-Administration 3AirStrip Sense4Baby System Receives FDA Clearance for Patient Self-Administration 4Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 2Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 3Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 4Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 5Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 6Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 7'Rx in Reach' Campaign Launches in Georgia 2'Rx in Reach' Campaign Launches in Georgia 3
... 6, 2012  Mylan Inc. (Nasdaq: MYL ) ... of two dermatological products from Valeant Pharmaceuticals. Mylan has ... Phosphate / Benzoyl Peroxide Gel, which is the generic ... manufactured and marketed the generic version of this product ...
... welcomes Michael Podany as Vice President of Sales, West USA ... Mr. Podany will be responsible for developing and managing sales ... Keith (GM, Director of Sales, USA). Mr. ... in creating, managing, and growing a new base of business ...
Cached Medicine Technology:Mylan Completes Acquisition of Two Limited-Competition Dermatological Products from Valeant 2Mylan Completes Acquisition of Two Limited-Competition Dermatological Products from Valeant 3Samsung Medison America Appoints Michael Podany as Vice President of Sales, West USA 2
... Revo Suture Anchor offers a simple and ... rotator cuff repair. The cutting tip requires ... with two #2 strands of braided polyester ... are avoided with the Independent Suture Sliding ...
The Atakr II RF Generator provides high power output with the integral safety of closed-loop temperature control using the embedded thermocouples in Medtronic RF ablation catheters....
... dedicated electrophysiology system on the market today, ... Fischer's patented "C inside a C" design ... the ultimate in patient access and flexibility. ... EPX2 minimizes equipment footprint and can be ...
... The requirements for Bi-Plane Electrophysiology imaging ... to decrease procedure time and reduce radiation ... become paramount in deciding between Single and ... goal of maintaining its leadership position in ...
Medicine Products: